|
|
| Bearsden Sells Technology to Message |
ASTON, Pa., Sept. 29 /PRNewswire/ -- Bearsden Bio, Inc. announces the sale
of a research division focusing on functional genomics to Message
Pharmaceuticals, Inc. The sale includes 3 patent applications covering
modulation of messenger RNA-protein interactions to regulate protein
expression levels and to identify new genes.
Bearsden is a growing biopharmaceutical company with a broad based
technology in nucleic acid and rational drug design. The company's present
expertise is in nucleic acid-based products -- from DNA and RNA building
blocks, to molecular biology, gene discovery and characterization kits,
oligonucleotides, oligomimetics, and drug leads. The company's chemists are
leaders at designing, synthesizing and manufacturing antisense and medicinal
chemistry products for research, diagnostic and therapeutic purposes. The
company has 12 patent or patent applications covering new technologies and
composition of matter and is focusing its efforts into bringing the
technologies and lead compounds to market.
In order to be at the forefront of biotechnology based drug design,
development and manufacturing, Bearsden is positioning itself to become the
partner of choice for pharmaceutical companies to collaborate in their
development efforts of drug intermediates and drug leads.
Bearsden plans to grow internally as well as through acquisitions and has
identified several merger candidates in the area of innovative biotechnology
reagents and drugs.
SOURCE Bearsden Bio, Inc.
back to topRelated links:
CONTACT:
Maria Maccecchini of Bearsden, 610-361-9224,
or Fax, 610-361-8255
